We postulate that therapy with vevorisertib will be able to treat a fully developed HCC by inhibiting the PI3K/AKT/mTOR pathway and may prevent/overcome the sorafenib resistance in HCCs. This evidence concerns the gene AKT1 and hepatocellular carcinoma.